260 related articles for article (PubMed ID: 18612701)
1. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Jpn J Clin Oncol; 2008 Aug; 38(8):528-33. PubMed ID: 18664479
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
Wiseman SM; Griffith OL; Melck A; Masoudi H; Gown A; Nabi IR; Jones SJ
Am J Surg; 2008 May; 195(5):667-73; discussion 673. PubMed ID: 18424286
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
7. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
9. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
10. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J
Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974
[TBL] [Abstract][Full Text] [Related]
12. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
[TBL] [Abstract][Full Text] [Related]
14. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Transl Res; 2008 Sep; 152(3):143-9. PubMed ID: 18774544
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical analysis for differential diagnosis of thyroid lesions using liquid-based cytology.
Hashimoto K; Morimoto A; Kato M; Tominaga Y; Maeda N; Tsuzuki T; Yokoi T; Nagasaka T
Nagoya J Med Sci; 2011 Feb; 73(1-2):15-24. PubMed ID: 21614933
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.
Montero-Conde C; Martín-Campos JM; Lerma E; Gimenez G; Martínez-Guitarte JL; Combalía N; Montaner D; Matías-Guiu X; Dopazo J; de Leiva A; Robledo M; Mauricio D
Oncogene; 2008 Mar; 27(11):1554-61. PubMed ID: 17873908
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
[TBL] [Abstract][Full Text] [Related]
18. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma.
Sethi K; Sarkar S; Das S; Rajput S; Mazumder A; Roy B; Patra S; Mohanty B; El-Naggar AK; Mandal M
J Exp Ther Oncol; 2011; 9(3):187-99. PubMed ID: 22070050
[TBL] [Abstract][Full Text] [Related]
19. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of 16 cellular tumor markers for metastatic thyroid cancer: an immunohistochemical study.
Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Zhan S; Xie K; Li QQ
Anticancer Res; 2011 Oct; 31(10):3433-40. PubMed ID: 21965758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
